Clinical Study on Raman Spectra of Blood, Saliva and Urine in Patients With Cancer Treated by Modern Therapy

• Conditions: Liver Cancer; Lung Cancer; Breast Cancer; Stomach Cancer

• Registration Number: NCT04215861
• Lead Sponsor: The First Affiliated Hospital of Dalian Medical University

Brief Summary

Blood, saliva and urine samples of tumor patients on the day of admission and discharge were collected for Raman spectral analysis, which provided exploration for the prediction of efficacy, follow-up and prognosis according to the variation characteristics of Raman spectral.

Detailed Description

Blood, saliva and urine samples of tumor patients on the day of admission and discharge were collected for Raman spectral analysis, which provided exploration for the prediction of efficacy, follow-up and prognosis according to the variation characteristics of Raman spectral

Study Timeline

• Study Start: 2019-10-01
• Status Verified: 2019-12
• Study First Submitted: 2019-12-11
• Study First Submitted QC: 2019-12-31
• Last Update Submitted: 2019-12-31
• Study First Posted: 2020-01-02
• Last Update Posted: 2020-01-02
• Primary Completion: 2021-10
• Study Completion: 2021-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• 18-80 years old;
• The patient whose tumor (tissue or cell) was first diagnosed by pathology;
• Plan to receive routine clinical treatment: chemotherapy, radiotherapy, surgery, intervention, targeted therapy, traditional Chinese medicine treatment and biological immunotherapy;
• Have relevant indications for treatment and have no contraindications;

Exclusion Criteria

• Severe or uncontrollable systemic diseases (such as unstable or uncompensated respiratory, heart, liver or kidney diseases, etc.);
• Other circumstances considered inappropriate by the researcher to participate in the study;

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Raman spectra	the 1st day after operation	Blood, saliva and urine samples of tumor patients on the day of admission and discharge were collected to analyze the signal changes of Raman spectrum

Secondary Outcome Measures

Name	Time	Method
overall survival	through study completion, an average of 1 year
progression-free survival	through study completion, an average of 1 year
objective response rate	through study completion, an average of 1 year

Trial Locations

Locations (1)

The First Affiliated Hospital of Dalian Medical University; 🇨🇳 Dalian, Liaoning, China